Detail akcie Nautilus Biotech Rg online

Business Summary: Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Nautilus Biotechnology Inc revenues was not reported. Net loss decreased 15% to $45.2M. Lower net loss reflects Laboratory segment loss decrease of 16% to $51.4M, United States segment loss decrease of 16% to $51.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.42 to -$0.36.